EFFICACY OF NOVEL ANTIMICROBIAL AGENTS AGAINST MULTI-DRUG RESISTANT BACTERIA

Background: The rise of multi-drug resistant (MDR) bacteria poses a significant threat to public health worldwide, undermining the efficacy of conventional antibiotics and escalating the severity of infections. Addressing this challenge requires the development of innovative antimicrobial agents that can effectively combat these resistant strains. Objective: To evaluate the efficacy of novel antimicrobial agents against isolated MDR bacteria from clinical samples, assessing their potential as viable therapeutic options. Methods: This experimental study was conducted at Nishtar Medical University Multan, with ethical approval from the hospital’s ethical board. Bacterial strains were isolated from various clinical samples and identified as MDR pathogens. The antimicrobial efficacy of three novel agents was assessed using minimum inhibitory concentration (MIC) tests and bactericidal assays, quantifying the agents' ability to inhibit and eradicate bacterial growth. Results: The novel agents demonstrated varying efficacy against the bacteria. Agent A showed a significant reduction in Klebsiella pneumoniae with 99.0% bactericidal activity. Agent B reduced Pseudomonas aeruginosa by 82.4%, while Agent C was particularly effective against Acinetobacter baumannii, with an MIC of 0.66 µg/ml. These results indicate the agents' potent antimicrobial properties across different MDR bacterial strains. Conclusion: The study highlights the promising potential of novel antimicrobial agents in treating infections caused by MDR bacteria. The significant bactericidal effects observed suggest these agents could be crucial in developing new therapeutic strategies against resistant pathogens.